JP2005531559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531559A5 JP2005531559A5 JP2004505099A JP2004505099A JP2005531559A5 JP 2005531559 A5 JP2005531559 A5 JP 2005531559A5 JP 2004505099 A JP2004505099 A JP 2004505099A JP 2004505099 A JP2004505099 A JP 2004505099A JP 2005531559 A5 JP2005531559 A5 JP 2005531559A5
- Authority
- JP
- Japan
- Prior art keywords
- crp
- group
- ligand
- condition
- pchpc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 238
- 102100032752 C-reactive protein Human genes 0.000 claims description 238
- 239000003446 ligand Substances 0.000 claims description 97
- 150000001875 compounds Chemical class 0.000 claims description 70
- 125000005647 linker group Chemical group 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 24
- 230000000451 tissue damage Effects 0.000 claims description 23
- 231100000827 tissue damage Toxicity 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 14
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 13
- 201000001320 Atherosclerosis Diseases 0.000 claims description 12
- 150000001412 amines Chemical group 0.000 claims description 8
- 230000004968 inflammatory condition Effects 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000000302 ischemic effect Effects 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 5
- 206010028851 Necrosis Diseases 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 238000002283 elective surgery Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
- 201000003229 acute pancreatitis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 2
- 206010070517 Type 2 lepra reaction Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 125000000743 hydrocarbylene group Chemical group 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000000366 juvenile effect Effects 0.000 claims description 2
- VSEKEMQDOIJVFY-UHFFFAOYSA-N n',n'-dimethylmethanediamine Chemical compound CN(C)CN VSEKEMQDOIJVFY-UHFFFAOYSA-N 0.000 claims description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 34
- 102100036202 Serum amyloid P-component Human genes 0.000 description 34
- 238000001727 in vivo Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 25
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 16
- 101000922020 Homo sapiens Cysteine and glycine-rich protein 1 Proteins 0.000 description 16
- 239000011575 calcium Substances 0.000 description 16
- 229910052791 calcium Inorganic materials 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 16
- 102000051143 human CRP Human genes 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 15
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 15
- 102000007330 LDL Lipoproteins Human genes 0.000 description 14
- 108010007622 LDL Lipoproteins Proteins 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241001135893 Themira Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 230000003993 interaction Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000024203 complement activation Effects 0.000 description 8
- 210000000497 foam cell Anatomy 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 102000002067 Protein Subunits Human genes 0.000 description 7
- 108010001267 Protein Subunits Proteins 0.000 description 7
- -1 hydroxy, 1-cyclopentanyl Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 6
- 229960001802 phenylephrine Drugs 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 5
- 108090001030 Lipoproteins Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229910001424 calcium ion Inorganic materials 0.000 description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- SBMUNILHNJLMBF-UHFFFAOYSA-N 2-chloro-1,3,2$l^{5}-dioxaphospholane 2-oxide Chemical compound ClP1(=O)OCCO1 SBMUNILHNJLMBF-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000010807 negative regulation of binding Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 231100000255 pathogenic effect Toxicity 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HDRSMDKMVQAIIM-UHFFFAOYSA-N CCCCCC.C[N+](C)(C)CCOP([O-])([O-])=O.C[N+](C)(C)CCOP(O)(O)=O Chemical compound CCCCCC.C[N+](C)(C)CCOP([O-])([O-])=O.C[N+](C)(C)CCOP(O)(O)=O HDRSMDKMVQAIIM-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 101001092908 Mus musculus Serum amyloid P-component Proteins 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002297 emergency surgery Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 230000006749 inflammatory damage Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- XGNBMSNJVYLEGI-UHFFFAOYSA-N C[N+](C)(C)CC(O)(P([O-])(O)=O)P(O)(O)=O Chemical compound C[N+](C)(C)CC(O)(P([O-])(O)=O)P(O)(O)=O XGNBMSNJVYLEGI-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- VQWWKYLNRCKQRP-UHFFFAOYSA-N N[Ca] Chemical compound N[Ca] VQWWKYLNRCKQRP-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 239000011985 first-generation catalyst Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002334 isothermal calorimetry Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- TXXHDPDFNKHHGW-ZPUQHVIOSA-N trans,trans-muconic acid Chemical compound OC(=O)\C=C\C=C\C(O)=O TXXHDPDFNKHHGW-ZPUQHVIOSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0211136.7A GB0211136D0 (en) | 2002-05-15 | 2002-05-15 | Treatment and prevention of tissue damage |
| PCT/GB2003/002096 WO2003097104A1 (en) | 2002-05-15 | 2003-05-14 | Treatment and prevention of tissue damage |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010022669A Division JP2010174013A (ja) | 2002-05-15 | 2010-02-04 | 組織ダメージの治療と予防 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531559A JP2005531559A (ja) | 2005-10-20 |
| JP2005531559A5 true JP2005531559A5 (enExample) | 2011-03-31 |
Family
ID=9936726
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505099A Ceased JP2005531559A (ja) | 2002-05-15 | 2003-05-14 | 組織ダメージの治療と予防 |
| JP2010022669A Pending JP2010174013A (ja) | 2002-05-15 | 2010-02-04 | 組織ダメージの治療と予防 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010022669A Pending JP2010174013A (ja) | 2002-05-15 | 2010-02-04 | 組織ダメージの治療と予防 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7615543B2 (enExample) |
| EP (1) | EP1503800B1 (enExample) |
| JP (2) | JP2005531559A (enExample) |
| AT (1) | ATE446761T1 (enExample) |
| AU (1) | AU2003234000B8 (enExample) |
| CA (1) | CA2485852C (enExample) |
| DE (1) | DE60329839D1 (enExample) |
| DK (1) | DK1503800T3 (enExample) |
| ES (1) | ES2333522T3 (enExample) |
| GB (1) | GB0211136D0 (enExample) |
| WO (1) | WO2003097104A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
| CN101845009B (zh) | 2002-07-29 | 2012-10-03 | 卡达克斯药物公司 | 用于抑制和改善疾病的类胡萝卜素结构类似物 |
| PT1596880E (pt) | 2002-12-23 | 2011-06-06 | Univ Rice William M | Métodos e composições para suprimir a diferenciação de fibrócitos |
| US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| US20070265196A1 (en) * | 2004-01-21 | 2007-11-15 | Medvet Science Pty., Ltd. | Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein |
| EP1582527A1 (en) * | 2004-03-31 | 2005-10-05 | Ciba SC Holding AG | Synthesis of phosphorus based ligands |
| CA2654440C (en) * | 2005-06-06 | 2013-09-03 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| ES2409756T3 (es) | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
| US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| EP2405929B1 (en) | 2009-03-11 | 2018-06-06 | Promedior Inc. | A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease |
| CA2754961C (en) | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
| UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| EP2987803B1 (en) | 2009-06-17 | 2018-08-29 | Promedior Inc. | Sap variants and their use |
| US8674027B2 (en) | 2009-09-18 | 2014-03-18 | Dow Global Technologies Llc | Powdered thermoplastic polyolefin elastomer composition for slush molding processes |
| WO2011155956A1 (en) | 2010-06-08 | 2011-12-15 | Dow Global Technologies Llc | Polyolefin elastomer composition for artificial leather applications |
| US20150087576A1 (en) * | 2011-12-14 | 2015-03-26 | The Texas A&M University System | Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap) |
| EP2890300B1 (en) | 2012-08-31 | 2019-01-02 | Kenji Suzuki | Supervised machine learning technique for reduction of radiation dose in computed tomography imaging |
| EP2957563A1 (en) * | 2014-06-19 | 2015-12-23 | Pentracor GmbH | Separation material comprising phosphoryl choline derivatives |
| GB202002299D0 (en) * | 2020-02-19 | 2020-04-01 | Pentraxin Therapeutics Ltd | Agents for use in the treatment of tissue damage |
| WO2021197371A1 (zh) * | 2020-03-31 | 2021-10-07 | 南京金斯瑞生物科技有限公司 | 一种含有刚性连接子的生物偶联物 |
| WO2022178594A1 (en) * | 2021-02-25 | 2022-09-01 | Baker Heart and Diabetes Institute | C-reactive protein inhibitors |
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
| KR20230060368A (ko) * | 2021-10-27 | 2023-05-04 | 솔브레인 주식회사 | 환형 포스핀 화합물의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4640913A (en) | 1983-01-10 | 1987-02-03 | American Cyanamid Company | Phosphocholine derivatives having antihypertensive action |
| IL84252A (en) | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
| US5811568A (en) | 1992-10-08 | 1998-09-22 | Shaman Pharmaceuticals, Inc. | Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity |
| US5681829A (en) | 1992-10-08 | 1997-10-28 | Shaman Pharmaceuticals, Inc. | Class of phosphocholine derivatives having antifungal activity |
| JP4524846B2 (ja) | 2000-04-20 | 2010-08-18 | 日油株式会社 | 化粧料 |
| US6764826B2 (en) | 2000-06-08 | 2004-07-20 | Board Of Regents, The University Of Texas System | Inhibitors of C-reactive protein induced inflammation |
| US7390795B2 (en) * | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
| JP4472333B2 (ja) | 2001-08-08 | 2010-06-02 | ペントラキシン セラピューティクス リミテッド | 好ましくないタンパク質群を患者の血漿から除去するための薬剤 |
| GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
-
2002
- 2002-05-15 GB GBGB0211136.7A patent/GB0211136D0/en not_active Ceased
-
2003
- 2003-05-14 DE DE60329839T patent/DE60329839D1/de not_active Expired - Lifetime
- 2003-05-14 ES ES03727670T patent/ES2333522T3/es not_active Expired - Lifetime
- 2003-05-14 US US10/514,127 patent/US7615543B2/en not_active Expired - Fee Related
- 2003-05-14 DK DK03727670.6T patent/DK1503800T3/da active
- 2003-05-14 JP JP2004505099A patent/JP2005531559A/ja not_active Ceased
- 2003-05-14 EP EP03727670A patent/EP1503800B1/en not_active Expired - Lifetime
- 2003-05-14 WO PCT/GB2003/002096 patent/WO2003097104A1/en not_active Ceased
- 2003-05-14 AT AT03727670T patent/ATE446761T1/de not_active IP Right Cessation
- 2003-05-14 CA CA2485852A patent/CA2485852C/en not_active Expired - Fee Related
- 2003-05-14 AU AU2003234000A patent/AU2003234000B8/en not_active Ceased
-
2010
- 2010-02-04 JP JP2010022669A patent/JP2010174013A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010174013A (ja) | 組織ダメージの治療と予防 | |
| JP2005531559A5 (enExample) | ||
| US20240124476A1 (en) | Molecular containers and methods of making and using same | |
| EP0956049B1 (en) | Conjugates of thrombin inhibitors and endogenous carriers | |
| WO2009036092A2 (en) | Mitochondria-targeted anti-tumor agents | |
| JP2009532338A (ja) | Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法 | |
| JP7691928B2 (ja) | キナーゼ阻害剤 | |
| US20100292183A1 (en) | Tetracycline and uses thereof | |
| US9566351B2 (en) | Molecular containers and methods of making and using same | |
| EP2841111A1 (en) | A nanosphere - histone acetyltransferase (hat) activator composition, process and methods thereof | |
| JP2012522017A (ja) | 診断適用および臨床適用のための癌胎児抗原／未熟ラミニン受容体抗体 | |
| KR20160145617A (ko) | 1,1''-(1,6-디옥소-1,6-헥산디일)비스-ｄ-프롤린의 프로드럭 | |
| JP2008531475A (ja) | アミノチオール含有分子をビヒクルと複合化する方法 | |
| WO2018122325A1 (en) | A system of collaborative modifiers and binders | |
| WO2025049143A1 (en) | Ionizable pillararene anticoagulant | |
| AU715746C (en) | Conjugates of thrombin inhibitors and endogenes carriers | |
| JP2022145661A (ja) | Ｐｄ－１及び／又はｐｄ－ｌ１の阻害剤 | |
| CN119970697A (zh) | 胡桃醌作为热休克蛋白90抑制剂在治疗胶质瘤中的应用 | |
| JP2013043874A (ja) | チューブリン結合剤 | |
| Moldovan et al. | Role of Heat Shock Factor-1 Activation in the Doxorubicin-induced 2 Heart Failure in Mice 3 | |
| RO127496B1 (ro) | Imunoconjugaţi cu încărcătură citotoxică naftalendionică antiproliferativă |